Method and composition for treating alzheimer-type dementia
First Claim
1. A composition comprising an acetyl choline esterase inhibitor (AChEI) selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine, and pharmaceutically acceptable salts thereof and a non-anticholinergic antiemetic agent, said AChEI being present at a level from 1.1 to 4 times greater than a recommended maximal dose level approved by the U.S. FDA.
0 Assignments
0 Petitions
Accused Products
Abstract
There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetyl choline esterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetyl choline esterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholine esterase inhibitor are also described.
27 Citations
14 Claims
- 1. A composition comprising an acetyl choline esterase inhibitor (AChEI) selected from the group consisting of tacrine, donepezil, rivastigmine, galantamine, and pharmaceutically acceptable salts thereof and a non-anticholinergic antiemetic agent, said AChEI being present at a level from 1.1 to 4 times greater than a recommended maximal dose level approved by the U.S. FDA.
- 11. A composition comprising an acetyl choline esterase inhibitor (AChEI) selected from the group consisting of donepezil and pharmaceutically acceptable salts thereof and a non-anticholinergic antiemetic agent consisting of a 5-HT3 receptor antagonist selected from the group consisting of granisetron and pharmaceutically acceptable salts and solvates thereof, said AChEI being present at a level from 1.1 to 4 times greater than a recommended maximal dose level approved by the U.S. FDA.
Specification